SCHEMBL5256129

SCHEMBL5256129

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OC(F)(F)F)c4noc(N)c34)cc2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.79
FLT3 P36888 16/20 0.79
KIT P10721 14/20 0.79
FLT1 P17948 8/20 0.67
CSF1R P07333 7/20 0.67
PDGFRB P09619 5/20 0.67
TEK Q02763 2/20 0.67
FLT4 P35916 6/20 0.54
LCK P06239 5/20 0.54
BLK P51451 5/20 0.54
AURKB Q96GD4 4/20 0.54
ROCK2 O75116 3/20 0.54
AXL P30530 3/20 0.54
FRK P42685 3/20 0.54
ROCK1 Q13464 3/20 0.54
HIPK2 Q9H2X6 3/20 0.54
CLK4 Q9HAZ1 3/20 0.54
MAP4K5 Q9Y4K4 3/20 0.54
CDK1 P06493 2/20 0.54
CSNK1G2 P78368 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394108 0.91 KDR (0.78) KDRFLT3KITFLT1CSF1R
SCHEMBL5253491 0.90 KDR (0.64) KDRFLT3KITFLT1CSF1R
SCHEMBL1380250 0.89 KDR (0.65) KDRFLT3KITFLT1CSF1R
SCHEMBL4740470 0.89 KDR (0.76) KDRFLT3KITFLT1CSF1R
SCHEMBL4740129 0.88 KDR (0.75) KDRFLT3KITFLT1CSF1R
SCHEMBL421372 0.88 KDR (1.00) KDRFLT3KITFLT1CSF1R
SCHEMBL5252618 0.85 KDR (0.60) KDRFLT3KITFLT1CSF1R
SCHEMBL1383935 0.83 KDR (0.62) KDRFLT3KITFLT1CSF1R
SCHEMBL4738177 0.82 KDR (0.64) KDRFLT3KITFLT1CSF1R
SCHEMBL5249393 0.82 KDR (0.63) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed